Alembic Pharmaceuticals, 533573, APLLTD Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

16,218.42
23.39
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

17,376.57
1.45%
2.77

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

8.89
6.72
5.65

EBITDA CAGR (%)

10 Years
5 Years
3 Years

6.16
5.04
3.69

PAT CAGR (%)

10 Years
5 Years
3 Years

5.19
5.31
3.09

P:E (Median)

8 Years
5 Years
3 Years

24.20
29.64
29.68

P:BV (Average)

8 Years
5 Years
3 Years

3.52
3.18
3.57

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.69
17.17
18.23

Earnings Forecasts:

(Updated: 15-08-2026)

Description 2026 2027 2028 2029
Adj EPS 42 9 16.21 34.69
P/E Ratio 19.63 91.62 50.87 23.77
Revenue 21.8 17.47 14.13 7418.6
EBITDA 8189.5 9068.69 9996.28 1190.45
Net Income 1306.54 1550.5 1861.1 672.47
ROA 736.44 919.96 1138.43 8.53
P/B Ratio 0.94 1.55 2.08 2.86
ROE 2.61 2.35 2.14 12.64
FCFF 12.42 14.04 16.65 451.92
FCFF Yield 519.42 618.33 2999.98 2.61
Net Debt 3 3.57 17.33 970.02
BVPS 873.5 531.12 396.8 288.06

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 1,868.06 1,494.17 25.02% 1,718.74 1,570.64 9.43% 1,642.24 1,406.09 16.79% 1,796.24 1,580.35 13.66%
Expenses 1,522.24 1,280.43 18.89% 1,444.67 1,399.98 3.19% 1,370.63 1,226.26 11.77% 1,492.93 1,320.86 13.03%
EBITDA 345.82 213.74 61.79% 274.07 170.66 60.59% 271.61 179.83 51.04% 303.31 259.49 16.89%
EBIDTM 18.51% 14.30% 15.95% 10.87% 16.54% 12.79% 16.89% 16.42%
Other Income 14.04 7.79 80.23% 25.88 13.21 95.91% 10.73 15.46 -30.60% 11.49 16.06 -28.46%
Interest 21.41 22.64 -5.43% 19.42 23.71 -18.09% 21.65 21.79 -0.64% 22.81 18.28 24.78%
Depreciation 82.54 73.37 12.50% 82.31 68.60 19.99% 79.67 69.69 14.32% 75.64 70.12 7.87%
PBT 255.91 125.52 103.88% 173.46 91.56 89.45% 138.78 103.81 33.69% 216.35 200.02 8.16%
Tax 58.95 22.00 167.95% -69.61 16.22 - 24.31 18.00 35.06% 36.99 34.24 8.03%
PAT 196.96 103.52 90.26% 243.07 75.34 222.63% 114.47 85.81 33.40% 179.36 165.78 8.19%
PATM 10.54% 6.93% 14.14% 4.80% 6.97% 6.10% 9.99% 10.49%
EPS 10.02 5.27 90.13% 12.36 3.83 222.72% 5.82 4.36 33.49% 9.12 8.43 8.19%

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 2,149.77 1,710.72 25.66% 1,847.72 1,769.64 4.41% 1,876.31 1,692.74 10.84% 1,910.15 1,647.98 15.91%
Expenses 1,817.91 1,429.38 27.18% 1,619.80 1,497.72 8.15% 1,582.81 1,432.52 10.49% 1,594.46 1,408.71 13.19%
EBITDA 331.86 281.34 17.96% 227.92 271.92 -16.18% 293.50 260.22 12.79% 315.69 239.27 31.94%
EBIDTM 15.44% 16.45% 12.34% 15.37% 15.64% 15.37% 16.53% 14.52%
Other Income 14.93 6.50 129.69% 25.50 14.19 79.70% 15.50 9.51 62.99% 6.91 16.74 -58.72%
Interest 27.61 23.52 17.39% 22.56 24.52 -7.99% 23.31 22.26 4.72% 24.23 18.81 28.81%
Depreciation 97.71 73.77 32.45% 88.59 68.99 28.41% 80.12 70.04 14.39% 76.07 70.51 7.89%
PBT 221.47 190.55 16.23% 117.51 192.60 -38.99% 163.34 177.43 -7.94% 222.30 179.56 23.80%
Tax 49.50 36.47 35.73% -82.91 35.31 - 29.55 40.08 -26.27% 40.01 27.28 46.66%
PAT 171.97 154.08 11.61% 200.42 157.29 27.42% 133.79 137.35 -2.59% 182.29 152.28 19.71%
PATM 8.00% 9.01% 10.85% 8.89% 7.13% 8.11% 9.54% 9.24%
EPS 8.81 7.85 12.23% 10.31 7.98 29.20% 6.77 7.04 -3.84% 9.40 7.80 20.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Net Sales 7,025.28 6,651.38 6,032.63 5,874.06 5,149.00 5,035.40 5,066.88 4,132.56 3,660.28 2,945.26 2,985.90 Net Sales Growth 16.10% 10.26% 2.70% 14.08% 2.26% -0.62% 22.61% 12.90% 24.28% -1.36% Cost Of Goods Sold 2,158.51 2,020.80 1,788.77 1,800.35 1,660.13 1,502.21 1,304.03 1,045.87 1,000.08 893.36 915.74 Gross Profit 4,866.77 4,630.58 4,243.86 4,073.71 3,488.87 3,533.19 3,762.85 3,086.69 2,660.20 2,051.90 2,070.16 GP Margin 69.28% 69.62% 70.35% 69.35% 67.76% 70.17% 74.26% 74.69% 72.68% 69.67% 69.33% Total Expenditure 5,830.47 5,589.14 5,136.55 4,876.27 4,484.97 4,126.63 3,617.71 2,940.87 2,800.98 2,346.65 2,353.36 Power & Fuel Cost - 177.44 179.67 173.32 151.19 120.50 118.31 97.43 88.44 70.21 64.13 % Of Sales - 2.67% 2.98% 2.95% 2.94% 2.39% 2.33% 2.36% 2.42% 2.38% 2.15% Employee Cost - 1,612.90 1,466.57 1,335.91 1,094.82 1,062.30 976.13 806.37 684.45 582.72 527.46 % Of Sales - 24.25% 24.31% 22.74% 21.26% 21.10% 19.26% 19.51% 18.70% 19.79% 17.67% Manufacturing Exp. - 446.51 397.72 348.85 386.28 374.69 369.82 323.09 254.55 226.57 241.01 % Of Sales - 6.71% 6.59% 5.94% 7.50% 7.44% 7.30% 7.82% 6.95% 7.69% 8.07% General & Admin Exp. - 626.64 535.51 497.23 464.08 390.16 377.29 311.21 319.33 269.55 283.40 % Of Sales - 9.42% 8.88% 8.46% 9.01% 7.75% 7.45% 7.53% 8.72% 9.15% 9.49% Selling & Distn. Exp. - 660.59 724.78 673.69 679.85 647.93 445.87 318.14 422.79 273.56 298.84 % Of Sales - 9.93% 12.01% 11.47% 13.20% 12.87% 8.80% 7.70% 11.55% 9.29% 10.01% Miscellaneous Exp. - 44.26 43.53 46.92 48.62 28.84 26.26 38.76 31.34 30.68 298.84 % Of Sales - 0.67% 0.72% 0.80% 0.94% 0.57% 0.52% 0.94% 0.86% 1.04% 0.76% EBITDA 1,194.81 1,062.24 896.08 997.79 664.03 908.77 1,449.17 1,191.69 859.30 598.61 632.54 EBITDA Margin 17.01% 15.97% 14.85% 16.99% 12.90% 18.05% 28.60% 28.84% 23.48% 20.32% 21.18% Other Income 62.14 56.37 53.19 32.05 3.85 51.17 84.08 145.96 25.79 40.59 3.28 Interest 85.29 86.51 76.47 54.47 49.00 17.02 12.98 25.19 14.87 2.22 3.21 Depreciation 320.16 311.00 277.08 271.14 272.95 284.92 182.53 135.67 105.59 101.76 82.90 PBT 784.50 721.10 595.72 704.23 345.93 658.00 1,337.74 1,176.79 764.63 535.22 549.71 Tax 50.64 13.69 105.47 37.75 -0.80 114.45 241.20 197.39 153.42 113.23 119.08 Tax Rate 6.46% 2.09% 17.33% 5.36% -0.23% 17.39% 18.03% 16.92% 20.06% 21.16% 21.66% PAT 733.86 640.42 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 PAT before Minority Interest 733.86 640.42 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 10.45% 9.63% 8.34% 11.35% 6.73% 10.79% 21.64% 23.46% 16.70% 14.33% 14.42% PAT Growth 70.49% 27.29% -24.51% 92.22% -36.21% -50.43% 13.12% 58.60% 44.84% -2.01% EPS 37.33 32.57 25.59 33.90 17.64 27.65 55.78 49.31 31.09 21.46 21.90

Description TTM Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Net Sales 7,783.95 7,344.90 6,672.08 6,228.63 5,652.62 5,305.78 5,393.14 4,605.76 3,934.69 3,130.81 3,134.61 Net Sales Growth 14.12% 10.08% 7.12% 10.19% 6.54% -1.62% 17.10% 17.06% 25.68% -0.12% Cost Of Goods Sold 2,197.12 1,984.45 1,793.36 1,715.08 1,708.82 1,446.43 1,257.35 1,039.38 992.71 886.19 887.57 Gross Profit 5,586.83 5,360.45 4,878.72 4,513.55 3,943.80 3,859.35 4,135.79 3,566.38 2,941.98 2,244.62 2,247.04 GP Margin 71.77% 72.98% 73.12% 72.46% 69.77% 72.74% 76.69% 77.43% 74.77% 71.69% 71.68% Total Expenditure 6,614.98 6,226.90 5,669.16 5,296.00 4,944.56 4,431.64 3,913.05 3,391.69 3,078.87 2,515.55 2,519.90 Power & Fuel Cost - 177.50 179.69 173.37 151.54 120.84 118.72 102.40 88.86 70.35 64.20 % Of Sales - 2.42% 2.69% 2.78% 2.68% 2.28% 2.20% 2.22% 2.26% 2.25% 2.05% Employee Cost - 1,731.93 1,562.34 1,446.29 1,169.13 1,133.00 1,051.17 906.44 746.69 622.81 558.83 % Of Sales - 23.58% 23.42% 23.22% 20.68% 21.35% 19.49% 19.68% 18.98% 19.89% 17.83% Manufacturing Exp. - 507.61 440.63 387.71 409.37 379.15 372.18 368.41 269.25 244.53 289.79 % Of Sales - 6.91% 6.60% 6.22% 7.24% 7.15% 6.90% 8.00% 6.84% 7.81% 9.24% General & Admin Exp. - 682.47 576.39 525.84 492.64 413.90 391.24 339.82 340.56 283.43 299.79 % Of Sales - 9.29% 8.64% 8.44% 8.72% 7.80% 7.25% 7.38% 8.66% 9.05% 9.56% Selling & Distn. Exp. - 1,083.11 1,064.86 996.88 952.30 890.38 687.41 531.19 590.28 380.21 393.14 % Of Sales - 14.75% 15.96% 16.00% 16.85% 16.78% 12.75% 11.53% 15.00% 12.14% 12.54% Miscellaneous Exp. - 59.83 51.89 50.83 60.76 47.94 34.98 104.05 50.52 28.03 393.14 % Of Sales - 0.81% 0.78% 0.82% 1.07% 0.90% 0.65% 2.26% 1.28% 0.90% 0.85% EBITDA 1,168.97 1,118.00 1,002.92 932.63 708.06 874.14 1,480.09 1,214.07 855.82 615.26 614.71 EBITDA Margin 15.02% 15.22% 15.03% 14.97% 12.53% 16.48% 27.44% 26.36% 21.75% 19.65% 19.61% Other Income 62.84 54.88 47.87 29.04 3.04 50.49 87.48 13.88 27.14 34.87 2.58 Interest 97.71 93.63 78.77 56.19 50.17 17.73 16.02 27.16 18.41 3.40 5.23 Depreciation 342.49 318.55 278.58 272.67 275.43 286.78 183.47 157.32 115.23 105.46 82.97 PBT 724.62 760.70 693.44 632.81 385.50 620.12 1,368.08 1,043.47 749.32 541.27 529.09 Tax 36.15 23.12 125.17 16.01 12.60 104.46 253.32 199.18 156.75 120.36 122.19 Tax Rate 4.99% 3.33% 17.72% 2.53% 3.27% 16.85% 18.52% 19.92% 20.92% 22.24% 23.09% PAT 688.47 674.77 583.42 615.82 341.99 520.94 1,114.76 828.76 593.65 420.72 406.99 PAT before Minority Interest 692.37 670.83 582.01 615.82 341.99 520.94 1,114.76 800.64 592.57 420.91 406.90 Minority Interest 3.90 3.94 1.41 0.00 0.00 0.00 0.00 28.12 1.08 -0.19 0.09 PAT Margin 8.84% 9.19% 8.74% 9.89% 6.05% 9.82% 20.67% 17.99% 15.09% 13.44% 12.98% PAT Growth 14.55% 15.66% -5.26% 80.07% -34.35% -53.27% 34.51% 39.60% 41.10% 3.37% EPS 35.02 34.32 29.68 31.32 17.40 26.50 56.70 42.15 30.20 21.40 20.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Shareholder's Funds 5,615.26 5,194.74 4,908.91 4,414.29 5,290.34 5,101.81 3,346.02 2,712.41 2,194.63 1,867.32 Share Capital 39.31 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 Total Reserves 5,575.95 5,155.43 4,869.60 4,374.98 5,251.03 5,062.50 3,308.32 2,674.71 2,156.93 1,829.62 Non-Current Liabilities 0.17 84.51 83.59 86.67 204.25 403.08 1,079.25 595.88 585.07 101.00 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 Long Term Provisions 152.91 124.31 109.51 106.20 95.82 85.52 73.21 51.32 40.43 57.22 Current Liabilities 2,425.02 2,285.86 1,368.40 1,551.30 1,694.45 1,378.36 1,649.99 1,397.76 1,011.69 658.79 Trade Payables 660.71 724.57 619.96 595.86 570.21 527.00 393.17 472.75 601.98 430.11 Other Current Liabilities 381.13 230.05 222.34 250.41 515.60 557.86 222.12 375.65 140.28 80.35 Short Term Borrowings 1,149.49 1,142.22 420.04 635.07 430.00 0.02 800.04 359.98 121.53 8.28 Short Term Provisions 233.69 189.02 106.06 69.96 178.64 293.48 234.66 189.38 147.90 140.05 Total Liabilities 8,040.45 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 6,075.26 4,706.05 3,791.39 2,627.11 Net Block 2,828.42 2,513.47 2,535.66 2,377.47 1,771.10 1,773.82 1,268.11 1,077.09 918.30 799.01 Gross Block 4,628.63 4,100.63 3,859.15 3,441.30 2,733.11 2,452.31 1,753.33 1,426.71 1,162.61 948.64 Accumulated Depreciation 1,800.21 1,587.16 1,323.49 1,063.83 962.01 678.49 485.22 349.62 244.31 149.63 Non Current Assets 3,940.58 3,712.65 3,331.16 3,272.05 4,329.58 4,148.87 3,727.40 2,713.03 2,002.20 1,286.33 Capital Work in Progress 683.40 837.23 524.36 601.28 2,304.24 2,182.53 1,569.98 1,106.89 740.64 347.75 Non Current Investment 271.40 259.56 226.68 229.27 219.36 156.12 833.25 506.39 298.89 103.04 Long Term Loans & Adv. 157.36 102.39 44.46 64.03 34.88 36.40 47.71 14.31 44.37 36.53 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 4,069.87 3,852.46 3,029.74 2,780.21 2,859.46 2,734.38 2,347.86 1,993.02 1,789.19 1,340.78 Current Investments 0.00 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 Inventories 2,048.16 1,976.34 1,353.07 1,275.13 1,396.83 1,341.95 1,073.18 891.42 669.93 574.62 Sundry Debtors 1,603.75 1,480.67 1,340.12 1,201.20 988.33 421.86 784.11 539.78 621.66 467.41 Cash & Bank 28.74 20.84 26.49 28.46 21.90 61.44 37.13 150.80 15.63 7.21 Other Current Assets 389.22 61.70 53.26 48.19 452.40 722.16 453.44 411.02 481.97 291.54 Short Term Loans & Adv. 331.33 312.91 256.80 227.23 407.69 650.61 431.08 397.95 458.60 285.95 Net Current Assets 1,644.85 1,566.60 1,661.34 1,228.91 1,165.01 1,356.02 697.87 595.26 777.50 681.99 Total Assets 8,010.45 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 6,075.26 4,706.05 3,791.39 2,627.11

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Shareholder's Funds 5,674.81 5,190.94 4,818.20 4,370.47 5,237.54 5,066.98 3,219.42 2,718.83 2,220.14 1,902.33 Share Capital 39.31 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 Total Reserves 5,635.50 5,151.63 4,778.89 4,331.16 5,198.23 5,027.67 3,181.72 2,681.13 2,182.44 1,864.63 Non-Current Liabilities 230.16 5.05 2.75 52.42 162.07 361.16 1,046.98 570.06 576.20 94.15 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 121.92 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 Long Term Provisions 152.91 124.31 109.51 106.20 95.82 85.52 74.51 52.03 40.76 57.22 Current Liabilities 2,686.87 2,514.27 1,520.28 1,640.80 1,830.59 1,533.26 1,954.22 1,663.65 1,267.18 813.96 Trade Payables 835.08 879.89 735.64 679.81 706.39 668.78 625.93 644.34 759.32 500.73 Other Current Liabilities 393.96 232.10 223.66 251.19 516.51 557.92 226.98 380.19 142.89 81.28 Short Term Borrowings 1,218.61 1,195.57 430.45 635.87 430.00 0.02 860.50 429.13 207.78 88.51 Short Term Provisions 239.22 206.71 130.53 73.93 177.69 306.54 240.81 209.99 157.19 143.44 Total Liabilities 8,586.01 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 6,191.66 4,951.75 4,063.83 2,810.55 Net Block 3,080.67 2,523.53 2,546.71 2,398.45 1,797.85 1,788.42 1,551.84 1,158.45 993.38 799.40 Gross Block 4,896.99 4,117.32 3,875.21 3,467.50 2,840.33 2,545.39 2,132.41 1,522.57 1,242.47 950.09 Accumulated Depreciation 1,816.32 1,593.79 1,328.50 1,069.05 1,042.48 756.97 580.57 364.12 249.09 150.69 Non Current Assets 3,920.38 3,519.12 3,197.39 3,149.80 4,255.37 4,056.96 3,526.30 2,820.02 2,116.31 1,316.80 Capital Work in Progress 683.40 837.23 524.36 601.28 2,304.24 2,182.53 1,846.18 1,551.23 1,010.15 396.28 Non Current Investment 140.88 127.21 93.02 96.33 118.40 49.31 17.62 48.76 41.64 49.88 Long Term Loans & Adv. 15.43 31.15 33.30 53.74 34.88 36.70 110.66 61.58 71.14 71.24 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 4,635.63 4,189.72 3,143.84 2,913.89 2,974.83 2,904.44 2,665.36 2,131.73 1,947.52 1,493.75 Current Investments 0.00 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 Inventories 2,510.65 2,288.14 1,643.54 1,475.27 1,609.70 1,486.15 1,187.54 967.27 733.93 632.75 Sundry Debtors 1,466.30 1,399.79 1,024.84 1,046.41 807.13 348.60 864.75 488.92 526.34 338.82 Cash & Bank 202.70 90.09 126.57 82.27 69.43 105.84 80.75 205.62 89.92 159.60 Other Current Assets 455.98 69.17 59.86 55.32 488.57 776.88 532.32 469.92 597.33 362.58 Short Term Loans & Adv. 375.22 342.53 289.03 254.62 436.92 698.21 504.22 451.71 569.84 355.02 Net Current Assets 1,948.76 1,675.45 1,623.56 1,273.09 1,144.24 1,371.18 711.14 468.08 680.34 679.79 Total Assets 8,556.01 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 6,191.66 4,951.75 4,063.83 2,810.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Cash From Operating Activity 809.46 226.57 772.77 730.25 545.26 1,388.48 539.75 808.80 304.55 327.16 PBT 654.11 608.59 704.23 345.93 658.01 1,337.74 1,166.79 764.63 535.22 549.71 Adjustment 428.45 365.07 284.21 448.49 413.35 92.60 30.14 91.48 81.90 84.88 Changes in Working Capital -193.57 -701.44 -205.64 -10.39 -397.30 198.56 -460.39 110.38 -188.46 -189.44 Cash after chg. in Working capital 888.99 272.22 782.80 784.03 674.06 1,628.90 736.54 966.49 428.66 445.15 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -79.53 -45.65 -10.03 -53.78 -128.80 -240.42 -196.79 -157.69 -124.11 -117.99 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -483.43 -636.08 -329.02 -460.98 -368.72 -835.72 -822.32 -753.60 -793.58 -510.97 Net Fixed Assets -374.17 -554.35 -340.93 994.77 -402.51 -1,311.53 -789.71 -630.35 -606.86 -121.60 Net Investments -11.84 -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 Others -97.42 -48.85 9.32 -1,445.84 -89.94 -14.35 294.25 84.25 9.13 -323.79 Cash from Financing Activity -317.59 403.61 -445.29 -261.16 -216.64 -533.75 166.13 79.67 497.80 -96.06 Net Cash Inflow / Outflow 8.44 -5.90 -1.54 8.11 -40.10 19.01 -116.44 134.87 8.77 -279.87 Opening Cash & Equivalents 14.23 20.13 21.67 13.56 53.66 35.58 144.25 9.45 0.68 280.56 Closing Cash & Equivalent 22.67 14.23 20.13 21.67 13.56 53.66 28.22 144.25 9.45 0.69

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Cash From Operating Activity 782.73 87.97 803.20 723.94 552.35 1,463.38 449.15 811.97 312.42 328.55 PBT 693.95 707.18 631.83 354.59 625.39 1,368.08 999.82 749.32 541.27 529.09 Adjustment 449.31 373.53 286.87 487.61 417.75 102.42 278.28 117.57 87.12 83.06 Changes in Working Capital -256.82 -921.36 -95.65 -57.56 -367.36 238.30 -592.84 111.56 -180.85 -165.64 Cash after chg. in Working capital 886.44 159.35 823.05 784.64 675.78 1,708.80 685.26 978.45 447.54 446.51 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -103.71 -71.38 -19.85 -60.70 -123.43 -245.42 -236.11 -166.48 -135.12 -117.96 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -506.06 -568.41 -320.61 -447.59 -371.97 -838.80 -731.63 -755.60 -884.38 -485.91 Net Fixed Assets -374.17 -554.35 -340.93 994.77 -402.51 -1,311.53 -789.71 -630.35 -606.86 -121.60 Net Investments -11.84 -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 Others -120.05 18.82 17.73 -1,432.45 -93.19 -17.43 384.94 82.25 -81.67 -298.73 Cash from Financing Activity -163.78 443.71 -437.86 -261.96 -217.35 -597.42 154.85 59.03 502.63 -128.88 Net Cash Inflow / Outflow 112.89 -36.73 44.73 14.39 -36.97 27.16 -127.63 115.40 -69.33 -286.24 Opening Cash & Equivalents 83.48 120.21 75.48 61.09 98.06 71.83 199.06 83.74 153.07 439.32 Closing Cash & Equivalent 196.37 83.48 120.21 75.48 61.09 98.06 71.84 199.07 83.74 153.08

Financial Ratios

Consolidated /

Standalone

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Book Value (Rs.) 285.69 264.30 249.75 224.59 269.16 259.57 177.51 143.89 116.43 99.06 ROA 8.21% 7.23% 10.74% 5.24% 7.73% 17.18% 18.32% 14.39% 13.15% 17.21% ROE 11.85% 9.96% 14.30% 7.15% 10.46% 25.96% 32.00% 24.91% 20.78% 25.35% ROCE 11.31% 11.74% 14.62% 7.20% 11.72% 25.40% 27.08% 23.66% 22.91% 32.46% Fixed Asset Turnover 1.56 1.55 1.61 1.67 1.94 2.41 2.59 2.82 2.79 2.94 Receivable days 82.69 83.47 78.96 77.61 51.11 43.44 58.46 57.91 67.48 51.27 Inventory Days 107.89 98.52 81.66 94.70 99.26 86.99 86.76 77.85 77.12 67.74 Payable days 125.11 137.18 123.25 128.19 133.30 128.78 54.44 74.24 86.97 79.07 Cash Conversion Cycle 65.47 44.82 37.36 44.12 17.08 1.65 90.78 61.52 57.63 39.94 Total Debt/Equity 0.20 0.22 0.09 0.14 0.12 0.10 0.50 0.39 0.28 0.00 Interest Cover 8.56 8.96 13.93 8.06 39.66 104.06 47.32 52.42 242.09 172.25

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Book Value (Rs.) 288.72 264.10 245.14 222.36 266.47 257.80 170.79 144.24 117.78 100.92 ROA 8.23% 8.28% 9.93% 5.15% 7.34% 17.22% 14.64% 13.15% 12.25% 14.97% ROE 12.35% 11.63% 13.40% 7.12% 10.11% 26.91% 26.97% 24.00% 20.42% 23.25% ROCE 11.74% 13.51% 13.42% 7.44% 11.25% 26.28% 23.30% 22.66% 22.15% 28.87% Fixed Asset Turnover 3.16 3.36 1.70 1.79 1.97 2.31 2.52 2.85 2.86 3.07 Receivable days 36.70 32.99 60.69 59.84 39.75 41.06 53.64 47.09 50.43 40.13 Inventory Days 61.45 53.50 91.38 99.60 106.49 90.48 85.38 78.91 79.67 70.01 Payable days 157.72 164.40 150.62 148.04 173.51 187.92 69.87 88.23 98.47 84.03 Cash Conversion Cycle -59.57 -77.92 1.45 11.40 -27.27 -56.39 69.15 37.76 31.63 26.12 Total Debt/Equity 0.24 0.23 0.09 0.15 0.12 0.10 0.54 0.42 0.32 0.05 Interest Cover 8.41 9.98 12.24 8.07 36.27 86.40 37.81 41.70 160.20 102.16

Top Investors:

life insurance corporation of india

dsp small cap fund

kotak small cap fund

icici prudential pharma healthcare and diaganostics (p.h.d) fund

tata aia life insurance co ltd unit linked multi cap fund

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Alembic Pharma - Quarterly Results
5th Aug 2026, 00:00 AM

Read More
Alembic Pharmaceuticals reports 12% rise in Q1 consolidated net profit
4th Aug 2026, 16:00 PM

Consolidated total income of the company increased by 26.06% to Rs 2,164.70 crore in Q1FY27
Read More
Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets
28th Jul 2026, 15:12 PM

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults
Read More
Alembic Pharmaceuticals' partner NATCO gets USFDA’s tentative nod for Olaparib Tablets
20th Jul 2026, 09:44 AM

The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Dapsone Gel
29th Jun 2026, 14:44 PM

Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA
Read More
Alembic Pharma gets USFDA’s approval for Oseltamivir Phosphate for Oral Suspension
29th Jun 2026, 11:44 AM

Alembic has a cumulative total of 243 ANDA approvals (223 final approvals and 20 tentative approvals) from USFDA
Read More
Alembic Pharma gets USFDA’s tentative nod for Binimetinib Tablets
19th Jun 2026, 15:43 PM

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Mektovi Tablets, 15 mg of Array
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Tretinoin Cream
12th Jun 2026, 14:49 PM

Tretinoin Cream USP, 0.05%, has an estimated market size of $76 million for twelve months ending March 2026 according to IQVIA
Read More
Alembic Pharmaceuticals gets USFDA’s tentative nod for Larotrectinib Capsules
11th Jun 2026, 15:15 PM

Larotrectinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors
Read More
Alembic Pharmaceuticals gets USFDA's final approval for Haloperidol tablets
5th Jun 2026, 12:00 PM

The company has a cumulative total of 240 ANDA approvals (221 final approvals and 19 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s final nod for Levothyroxine Sodium Tablets
22nd May 2026, 12:00 PM

Levothyroxine sodium tablets are indicated as a replacement therapy in primary, secondary, and tertiary congenital or acquired hypothyroidism
Read More
Alembic Pharmaceuticals gets EIR from USFDA for Injectable facility in Gujarat
14th May 2026, 12:10 PM

The USFDA had conducted an unannounced cGMP inspection from February 9, 2026 to February 18, 2026
Read More
Alembic Pharmaceuticals gets USFDA’s tentative nod for Darolutamide Tablets
14th May 2026, 11:18 AM

The approved ANDA is therapeutically equivalent to the reference listed drug product, Nubeqa Tablets, 300 mg, of Bayer
Read More

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: